Wedbush downgraded Tourmaline Bio (TRML) to Neutral from Outperform with an unchanged $48 price target after the company entered into a merger agreement with Novartis (NVS), pursuant to which Novartis will acquire Tourmaline for $48.00 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Novartis Seals $1.4B Deal with Tourmaline Bio (TRML) to Bolster Heart Disease Portfolio
- Tourmaline Bio Merges with Novartis for $1.4 Billion
- Tourmaline Bio to be acquired by Novartis for $48.00 per share in cash
- Tourmaline Bio’s Promising Drug Developments and Strategic Positioning Make It a Top Pick for 2024
- Tourmaline Bio’s Pacibekitug: A Promising Contender in ASCVD Treatment with Undervalued Potential